Luis Oliver Gómez
Directeur/Membre du Conseil chez Cellerix SA
Profil
Luis Oliver Gómez is currently a Director at Cellerix SA, Grupo Empresarial Enhol SL, and Principal at Capital Navarra SA. He was a Proprietary Director at Audax Renovables SA and a Director at Tecnología Energía Recuperada Navarra SL.
Postes actifs de Luis Oliver Gómez
| Sociétés | Poste | Début |
|---|---|---|
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Directeur/Membre du Conseil | 25/11/2009 |
| Capital Navarra SA | Corporate Officer/Principal | 25/11/2009 |
Grupo Empresarial Enhol SL
 Grupo Empresarial Enhol SL Alternative Power GenerationUtilities Grupo Empresarial Enhol SL develops and constructs power generation facilities. Its portfolio consists of wind farms, solar parks, and cogeneration plants, which it also operates and maintains. The company was founded in 1930 and is headquartered in Tudela, Spain. | Directeur/Membre du Conseil | - |
Anciens postes connus de Luis Oliver Gómez
| Sociétés | Poste | Fin |
|---|---|---|
Tecnología Energía Recuperada Navarra SL
 Tecnología Energía Recuperada Navarra SL Electric UtilitiesUtilities Tecnologia Energia Recuperada Navarra SL develops, constructs and operates power generation facilities. Its cogeneration plants convert waste materials, such as rubber tires and automotive scrap metal into electricity. Tecnologia Energia Recuperada Navarra was founded in 2004 and is headquartered in Tudela, Spain. | Directeur/Membre du Conseil | - |
| AUDAX RENOVABLES, S.A. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AUDAX RENOVABLES, S.A. | Utilities |
| Entreprise privées | 4 |
|---|---|
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Health Technology |
| Capital Navarra SA | |
Tecnología Energía Recuperada Navarra SL
Tecnología Energía Recuperada Navarra SL Electric UtilitiesUtilities Tecnologia Energia Recuperada Navarra SL develops, constructs and operates power generation facilities. Its cogeneration plants convert waste materials, such as rubber tires and automotive scrap metal into electricity. Tecnologia Energia Recuperada Navarra was founded in 2004 and is headquartered in Tudela, Spain. | Utilities |
Grupo Empresarial Enhol SL
Grupo Empresarial Enhol SL Alternative Power GenerationUtilities Grupo Empresarial Enhol SL develops and constructs power generation facilities. Its portfolio consists of wind farms, solar parks, and cogeneration plants, which it also operates and maintains. The company was founded in 1930 and is headquartered in Tudela, Spain. | Utilities |
